After preclinical trials of this new anti-cancer vaccine were successful in both safety and high efficacy.
The vaccine has undergone three years of international preclinical studies, which have shown it to be completely safe even after repeated injections, and highly effective in inhibiting tumor growth.
The results were astonishing, with tumor size and growth rates reduced by 60-80%. Remarkably, the vaccine also significantly improved patient survival rates.
The highlight of this vaccine is its ability to directly affect the immune system, helping the body recognize and fight cancer cells.
Illustration: AI
Pending clinical approval
By the end of the summer of 2025, FMBA submitted all the documents to the Russian Ministry of Health to request permission to use the vaccine on patients. This means that in a very short time, if approved, the vaccine could begin testing in hospitals and oncology centers, according to TASS news agency.
The first target is colorectal cancer.
In the first phase, the vaccine is being targeted at colorectal cancer - one of the most common cancers in the world. In parallel, scientists are also perfecting the development of vaccines against glioblastoma - one of the most malignant tumors, and special types of melanoma.
Cancer vaccine ready for use
According to Ms. Skvortsova, the highlight of this vaccine is its ability to directly affect the immune system, helping the body recognize and fight cancer cells. This is a new direction compared to traditional methods such as chemotherapy or radiotherapy.
The vaccine is ready for use, we are just waiting for the license, Skvortsova said. If it is implemented in clinical practice, it could become one of the most important breakthroughs in Russian medicine in cancer treatment.
Source: https://thanhnien.vn/nga-vac-xin-ung-thu-giam-80-khoi-u-da-san-sang-su-dung-185250907160008105.htm
Comment (0)